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Biochemical outcomes after robot-assisted radical
prostatectomy in patients with follow-up more than
5-years
Kwang Hyun Kim, Sey Kiat Lim, Tae-Young Shin, Byung Ha Chung, Sung Joon Hong and Koon Ho Rha
In this study, we assessed biochemical outcomes after robot-assisted radical prostatectomy (RARP). Between July 2005 and November
2007, one hundred and seventy-six consecutive patients treated by RARP without neoadjuvant treatment were included in this study. All
procedures were performed by a single surgeon and the median follow-up period was 60 months (interquartile range (IQR): 59–69). The
median prostate specific antigen was 7.50 ngml21 (IQR: 5.14–11.45) and 39.2% of the patients were classified as intermediate risk and
15.3% were classified as high risk; on final pathological examination, 35.2% of the patients had non-organ confined disease and 37.5%
and 14.2% had Gleason scores of 7 and 8–10, respectively. The biochemical recurrence (BCR)-free survival rates at 3 and 5 years were
85.6% and 81.2%, respectively. The 5-year BCR-free survival rates stratified by pathologic Gleason scores were 93.1% in Gleason scores
of 6 or less, 74.5% in a Gleason score of 7, and 58.1% in Gleason scores of 8 or greater, respectively (P,0.001). When stratified by
pathologic stage, the BCR-free survival rates were 89.8% in pT2 patients, 66.2% in pT3a patients, and 39.3% in pT3b patients at 5 years
following RARP, respectively (P,0.001). Preoperative prostate-specific antigen (PSA), pathologic stage, postoperative Gleason score and
surgical margin status were independently associated with BCR in multivariate analysis. In this study, we report biochemical outcomes
after RARP with the longest follow-up periods to date in Asian men. We found that robotic surgery provided satisfactory biochemical
outcomes, and that RARP is a safe and effective procedure in terms of oncologic outcomes.
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INTRODUCTION
Radical prostatectomy is a mainstay treatment for men with localized
prostate cancer with a demonstrated survival advantage1 and surgical
techniques have been refined by a number of advances in the past
decades.2–4 Following the introduction of robot-assisted laparoscopic
techniques,5 the use of robot-assisted radical prostatectomy (RARP)
has rapidly increased in the United States and Europe.6,7 Robotic
systems were first installed in a few Asian centers in 2004–2005, but
the acceptance of RARP in Asia has been slower than Western coun-
tries for several reasons, such as cost, insurance, or public policy.8
Given the natural history of prostate cancer and the relatively recent
adoption of robotic techniques, the oncologic outcomes after RARP
have not been sufficiently assessed compared with open series, which
have included more than 10 years of follow-up.9,10 Recently, several
studies have reported the biochemical outcomes of RARPs with more
than 5 years of median follow-up.11–13 Evaluating the oncologic out-
comes of RARP has great significance in several aspects. As one of the
standard treatments of prostate cancer, effective oncologic control is
of paramount importance. In addition, the outcomes of prostate can-
cer are influenced not only by treatment modality, but also by patient
characteristics. Considering the rapid and wide assimilation of robotic
techniques in the treatment of prostate cancer, the oncologic out-
comes after RARP may reflect the oncologic outcomes of contempo-
rary populations.
After the initial use of RARP in Korea at Yonsei University on 15 July
2005, one thousand and thirty-six patients underwent RARP by a single
surgeon (KHR) until December 2011, the largest single surgeon series in
Asian men.14 While several studies have reported on the feasibility,
technical aspects, or functional outcomes of RARP,14–16 the current body
of published literature is insufficient on the oncologic outcomes after
RARP in Asian men, especially with long-term follow-up. Thus, in this
study, we examined the biochemical outcomes in patients who under-
went RARP between 2005 and 2007. All surgeries were performed by a
single surgeon and the median follow-up was 5 years.
MATERIALS AND METHODS
From July 2005 to December 2011, one thousand and thirty-six
patients with prostate cancer underwent RARP by a single surgeon
(KHR). All data was collected prospectively into an electronic database
and analysed after obtaining institutional review board approval (4-
2012-0706). There were 191 patients who underwent RARP between
July 2005 and November 2007 and were eligible for follow-ups more
than 5 years. Sixteen patients who had received neoadjuvant treatment
were excluded, leaving 176 eligible men as the study cohort.
Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea
Correspondence: Dr KH Rha (khrha@yuhs.ac)
Received: 20 November 2012; Revised: 24 December 2012; Accepted: 2 February 2013; Published online: 25 March 2013
Asian Journal of Andrology (2013) 15, 404–408
 2013 AJA, SIMM & SJTU. All rights reserved 1008-682X/13 $32.00
www.nature.com/aja
All patients underwent preoperative staging with computed tomo-
graphy or magnetic resonance imaging and bone scan, which con-
firmed no evidence of metastatic disease. RARP was performed via a
transpertioneal approach using the daVinci Surgical System (Intuitive
Surgical, Sunnyvale, CA, USA). We routinely placed six trocars and
the port configuration was described in detail in our previous report.14
Excluding the initial 26 patients, standard lymph node dissection
including the external iliac, obturator and infraobturator area was
carried out during the study period regardless of the risk of lymph
node metastasis. Prostatectomy specimens were fixed and processed
using the whole mount technique with 3–5 mm transverse sections.
Extraprostatic extension was defined as the extension of cancer into
the periprostatic soft tissue and the presence of tumour cells at the
inked margin was considered as a positive surgical margin.
After surgery, prostate-specific antigen (PSA) was assessed every
three months for the first year and semi-annually thereafter.
Biochemical recurrence (BCR) was defined as the detection of serum
PSA greater than 0.2 ng ml21 with a secondary confirmatory increase
at least 6 weeks after surgery. Subsequent treatments such as radio-
therapy or hormonal therapy were not performed in the adjuvant
setting and were delayed until documented biochemical failure.
Clinicopathological variables including age, body mass index, pre-
operative PSA, clinical stage and biopsy Gleason score, as well as
postoperative variables including postoperative Gleason score, patho-
logic stage, surgical margin status and the presence of lymph node
invasion were assessed. The BCR-free survival rate was calculated by
Kaplan–Meier analysis and compared among groups using the log-
rank test. Of the 150 patients who underwent lymph node dissection,
only 4 (2.6%) patients had lymph node metastases. The presence of
lymph node metastases was not included in the analysis of BCR-free
survival rate due to the small number of patients with lymph node
metastases. The Cox proportional hazard regression model was used
to estimate the impact of clinicopathological variables on BCR-free
survival. PSA, pathologic stage, pathologic Gleason score and surgical
margin status were incorporated inmultivariate analysis and the back-
ward elimination method was used.
The Statistical Package for Social Science forWindows, version 18.0
(SPSS, Chicago, IL, USA)was used for all statistical analyses. AP,0.05
was considered significant, and all P values were two-sided.
RESULTS
Clinicopathological characteristics of all patients are summarized in
Table 1. The median age was 63 years (interquartile range (IQR): 59–
69) and median PSA was 7.50 ng ml21 (IQR: 5.14–11.45). A total of
39.2% of the patients were deemed intermediate risk and 15.3% of the
patients were deemed high risk according to D’Amico risk stratifica-
tion risk criteria.17 On postoperative pathologic examination, 62
(35.2%) had non-organ confined prostate cancer and the Gleason
score was 7 in 66 patients (37.5%) and 8 or greater in 25 patients
(14.2%), respectively. Of 110 patients with a biopsy Gleason score of
6, upgrading of the Gleason score was observed in 31 patients (28.1%),
of which 25 patients (22.7%) were upgraded to a Gleason score of 7
(22.7%) and 6 patients (5.5%) to 8–10. Positive surgical margins were
found in 59 patients (33.5%). The incidence of positive surgical mar-
gins was 17.5% in pT2 and 62.9% in pT3, respectively. Of the 150
patients who underwent lymph node dissection, 4 (2.6%) patients had
lymph node metastases.
At the time of analysis, the median follow-up was 60 months (IQR:
54–65) and 150 patients (85.2%) had a minimum of 3 years of follow-
up. Thirty-three (18.7%) patients experienced BCR and the 3- and 5-
year BCR-free survival rates were 85.6% and 81.2%, respectively in all
of the patients (Figure 1). The 3- and 5-year BCR-free survival rates
stratified by pathologic Gleason scores were 96.2% and 93.1% in
Gleason scores of 6 or less, 82.3% and 74.5% in a Gleason score of
7, and 62.6% and 58.1% in Gleason scores of 8 or greater, respectively
(P,0.001, Figure 2a). When stratified by pathologic stage, the BCR-
free survival rates were 91.8% and 89.8% in pT2 patients, 79.1% and
66.2% in pT3a patients, and 58.9% and 39.3% in pT3b patients at 3
Table 1 Clinical and pathological characteristics of all patients
No. patients (n5176)
Median age, year (IQR) 63 (59–69)
Median PSA, ng ml21 (IQR) 7.50 (5.14–11.45)
Median BMI, kg m22 (IQR) 24.3 (22.6–26.0)
Clinical stage, n (%)
T1 149 (84.7)
oT2 27 (15.3)
Biopsy Gleason score, n (%)
f6 110 (62.5)
7 43 (24.4)
o8 23 (13.1)
Risk category, n (%)
Low 80 (45.5)
Intermediate 69 (39.2)
High 27 (15.3)
Pathologic stage, n (%)
T2 114 (64.8)
T3a 51 (29.0)
T3b 11 (6.2)
Pathologic Gleason score, n (%)
f6 85 (48.3)
7 66 (37.5)
o8 25 (14.2)
Lymph node invasion, n (%) 4 (2.3)
Positive surgical margin, n (%) 59 (33.5)
Median prostate weight, g (IQR) 31.6 (25.4–42.1)
Abbreviations: BMI, body mass index; IQR, interquartile range; PSA, prostate-
specific antigen.
Figure 1 Kaplan–Meier curve of biochemical recurrence-free survival in all
patients.
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and 5 years following RARP, respectively (P,0.001,Figure 2b). The 3-
and 5-year BCR-free survival rates were 91.1% and 88.7% in patients
with negative surgical margins and 76.3% and 65.8% in patients with
positive surgical margins, respectively (P,0.001, Figure 2c). Of four
patients who had lymph node metastases, PSA did not reach unde-
tectable levels in two patients and the other two patients experienced
BCR at 9 and 11 months respectively after surgery.
The results of univariate and multivariate Cox regression analysis
were summarised in Table 2. On multivariate analysis, PSA (hazard
ratio (HR): 1.02, P,0.001), pathologic stage (HR for T3a vs. T2: 1.12,
P50.629; HR for T3b vs. T2: 3.14, P50.011), pathologic Gleason score
(HR for 7 vs.f6: 2.13,P50.094; 8 vs.f6: 3.57,P50.008) and positive
surgical margin (HR: 2.26, P50.035) were independently associated
with BCR.
DISCUSSION
Several studies have reported the oncologic outcomes after RARP.18–20
Even though these series reported favourable biochemical outcomes,
most were based on short-term follow-ups with medians less than 3
years. Recently, Menon et al.12 published the oncologic outcomes of
1384 patients who underwent RARP with a median 5-year follow-up.
Subsequently, Suardi et al.13 and Sooriakumaran et al.11 reported the
biochemical outcomes after RARP in European men with a minimum
follow-up of 5 years. Despite the slightly different pathologic features
and inclusion criteria, the 5 years BCR-free survival rates in those
studies were 86%–87%. It seems therefore that RARP can achieve
oncologic outcomes comparable to an open approach.
In this series, we examined the biochemical outcomes of 176
patients after RARP with amedian follow-up of 5 years. In our cohort,
BCR-free survival rates were 85.6% and 81.2% at 3 and 5 years,
respectively. This finding is inconsistent with recent reports of the
long-term outcomes after RARP, with the BCR-free survival rates in
the current series seemingly inferior to published results.11–13
However, our series included a higher proportion of high-grade di-
sease and non-organ confined tumours compared with those in recent
RARP series. Indeed, 14.2% of our patients hadGleason scores of 8–10
and approximately 35% had non-organ confined tumours. Although
the surgeon’s preferencesmay have contributed to themore aggressive
patient characteristics in this study, recent reports from single or
multi-institution studies in Korea have demonstrated similar patho-
logic characteristics and biochemical outcomes to our series.21,22 The
median PSA was also relatively high in this study. In another multi-
institutional study from Korea, patients were grouped by the year of
surgery, and the median value of PSA was 10.0 ng ml21 in one group
(1995–2003) and 7.5 ng ml21 in the other group (2004–2007), respec-
tively.23 Despite a rather high PSA, more contemporary population
cohorts presented with lower PSA levels and our results were similar
with the latter group. The increased use of the PSA test may have
contributed to a trend toward decreasing PSA at diagnosis and this
trend is expected to continue.
Nevertheless, we believe that the higher proportion of high grade in
this study is in large part due to ethnic differences in prostate cancer
that have been well described in published reports. Reviewing the
literature, a multi-institutional study performed in Korea showed that
a significant proportion of prostate cancer exhibited poor differentiation.24
Figure 2 Kaplan–Meier curves of biochemical recurrence-free survival stratified by postoperative Gleason score (a), pathologic stage (b) and surgical margin status (c).
Table 2 Univariate and multivariate Cox proportional hazard regression model for risk of biochemical recurrence
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
PSA 1.03 (1.02–1.04) ,0.001 1.02 (1.01–1.04) ,0.001
Pathologic stage ,0.001 0.012
T2 1 1
T3a 3.34 (1.67–6.67) 0.001 1.12 (0.53–2.77) 0.629
T3b 9.38 (4.45–19.79) ,0.001 3.14 (1.30–7.57) 0.011
Pathologic GS ,0.001 0.026
f6 1 1
7 3.55 (1.55–8.13) 0.003 2.13 (0.87–5.15) 0.094
o8 8.24 (3.62–18.75) ,0.001 3.57 (1.39–9.14) 0.008
Positive surgical margin 3.64 (1.97–6.75) ,0.001 2.26 (1.06–4.85) 0.035
Abbreviations: CI, confidence interval; GS, Gleason score; HR, hazard ratio; PSA, prostate-specific antigen.
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A significant proportion of high-grade disease was also noted in stu-
dies of Chinese and Japanese populations.25,26 Even in patients who
underwent radiotherapy, Asian men had twice the percentage of di-
sease with Gleason scores of 8 or greater compared with non-Asian
men.27 Pathologic Gleason scores of 8–10 is one of the most influential
determinants for BCR. A greater portion of patients with high-grade
disease may have affected the outcomes in this study. When stratified
by pathologic stage or Gleason score, the biochemical outcomes of our
series seemed similar with the results of previous RARP11–13 or
open28–30 series. Regarding the relatively high incidence of positive
surgical margin in this study, this may be partly associated with imma-
ture surgical techniques as initial cases of RARP were included in this
study. However, other radical prostatectomy series on Korean or
Japanese men have also showed similar incidences of positive surgical
margins, ranging from 32% to 35%.22,31,32 A significant proportion of
these tumours were poorly differentiated and it may have contributed
to the higher incidence of positive surgical margins. Moreover, pro-
state sizes of Asian men are smaller than Western men and smaller
prostate sizes have been demonstrated to be independently associated
with a higher incidence of positive surgical margins.33
While the incidence of prostate cancer is relatively low in Asian
men, it has been increasing over the years.34,35 Currently, Korea has
the largest number of robotic systems in Asia, and RARP is rapidly
gaining acceptance in the urologic community in other Asian coun-
tries.8 With regards to the oncologic outcomes after RARP, there are
only a few Asian studies, and most have short-term follow-up.
Recently, Yip et al.36 reported 235 patients treated with RARP between
2005 and 2009 in Hong Kong, China. However, the mean follow-up
period was 24 months and the biochemical outcomes were not ana-
lysed in detail. Although our group has previously reported the onco-
logic outcomes after RARP with more detailed pathologic variables
such as perineural invasion and lymphovascular invasion, the median
follow-up did not exceed 2 years. In another large series for a single
surgeon in Korea, which compared the functional outcomes between
robotic and open prostatectomy, the oncological outcomes were not
fully analysed due to insufficient length of follow-up.15
In this study, we assessed the biochemical outcomes after RARP of a
single surgeon series. In the oncological outcome assessment, suf-
ficient follow-up is critical and we included the initial patients who
underwent RARP between 2005 and 2007. The median follow-up of
these patients was 5 years, which was to our knowledge the longest
follow-up after RARP in an Asian population. Moreover, the current
study was based on a contemporary population and all procedures
were performed by a single surgeon with consistent technique. All
patients were followed according to a uniform protocol and no
patients received secondary treatment in an adjuvant setting.
Including or excluding patients treated with adjuvant therapy whom
harboured more aggressive tumour characteristics may skew the
results. Our results provide unbiased evidence for the biochemical
outcomes after RARP.
Our study has limitations. Although the current series has the
potential advantage of being from a single surgeon series, it may not
be representative of contemporary Korean or Asian populations. In
addition, BCR does not necessarily accompany clinical progression or
death from cancer and the median follow-up of 5 years is not long
enough to assess more meaningful outcomes such as metastasis-free
survival or cancer-specific survival. Finally, the effect of the learning
curve was not reflected in the analysis of biochemical outcomes. This
study included the learning curve of initial patients and may have
overestimated the BCR. Nevertheless, the present study represents
the largest series with the longest follow-up to date examining the
oncological outcomes of Asian men following RARP. Although the
present study is a single-arm analysis, the evidence suggests that
robotic surgery provides effective oncological outcomes. Further ana-
lysis is required to determine long-term oncological outcomes such as
metastases-free survival and cancer-specific mortality.
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